Immediate Reports All 2020 2021 2022 2023 2024 Voluntary Report on Q3 2024 Revenue; Company to Cease Quarterly Results Reporting Results of the General Meeting from 20.8.24 Calling of general Meeting for August 20, 2024 Engagement in an addendum to the investment agreement with Y.B. Contractors – return of investment Voluntary report on the company’s revenue for the first quarter of 2024 Results of a general meeting from 3/17/24 A meeting called for March 10, 2024 is postponed to March 17, 2024 Calling of Annual Meeting for March 10, 2024 A meeting called for March 6, 2024 is postponed to March 10, 2024 A meeting called for February 28, 2024 is postponed to March 6, 2024 Calling of Annual Meeting for February 28, 2024 A meeting called for February 26, 2024 is postponed to February 28, 2024 A meeting called for February 19, 2024 is postponed to February 26, 2024 A meeting called for February 14, 2024 is postponed to February 19, 2024 Calling of Annual Meeting for February 14, 2024 Agreement for the sale of shares of a joint venture company to Good Pharm for NIS 450 A voluntary report on the company’s revenues for the third quarter of 2023 in a total sum of approximately NIS 26.5 million Results of General Meeting held on July 26, 2023 A meeting called for 7/13/23 is postponed to 7/19/23 A meeting called for July 6, 2023 is postponed until July 13, 2023 A voluntary report on the company’s revenues for the first quarter of 2023 in a total sum of approximately NIS 21 million Calling of Special Meeting for December 13, 2022 – Company Anouncement Estimated revenue for the third quarter of 2022 in the amount of approximately NIS 7.5 million and updates related to the company’s activities Decisions of the company’s board of directors and its committees Results of General Meetingheld on July 6, 2022 Another import permit received for 850 kgs of medical cannabis from the Uganda farm to Israel Calling of Annual Meeting for July 6. 2022 – Company Anouncement Cuttings exported from the farm in Israel have reached the farm in Uganda Receipt of import permit for the company’s products from Germany to England Shipment from the Uganda farm received by the plant in Germany Engagement in an agreement for the investment of ILS 10 million in the company, against allotment of some 9.97 million shares and 2.49 million warrants Subsidiary receives approval for a plan in the grants track of the Ministry of Economy and Industry Understandings for the acquisition of approx. 51% in a pharmacy holding a license to sell medical cannabis Receipt of import permit for medical cannabis cuttings from Israel to the Uganda farm – Update Results of General Meeting held of March 17, 2022 Another permit received from Germany for the import of inflorescences grown in the Uganda farm Receipt of import permit for medical cannabis cuttings from Israel to the Uganda farm Facility receives 700 kg of medical cannabis from Uganda Subsidiary Globus Pharma receives approval from the IMCA to operate a laboratory thereof under the IMC-GMP standard Another permit received for import of 700 kgs of medical cannabis from the company’s farm in Uganda, effective until March 8, 2022 Letter to shareholders Closing of convertible loan agreement in the sum total of ILS 25 million with Y.H. Dimri Investments Results of General Meeting held on Dec 8, 2021 Initial sale of the company’s products in pharmacies in Germany and negotiations for other significant transactions in the German market A meeting convened on 6.12.21 is adjourned to 8.12.21 Commencement of marketing in Germany of the raw material from the farm in Uganda Calling of Special Meeting for Dec 6, 2021 Loan and convertible loan agreement for a total of ILS 25 million with a company controlled by Yigal Dimri (superseding previous agreement) First shipment to Germany sent from the company’s farm in Uganda Winning of tender for the supply of oils to the main pharmacy of the Israel Prison Service, together with another cannabis company Results of General Meeting held on Oct 6, 2021 Meeting convened on 26.9.21 is postponed to 6.10.21 – completion of regulatory inquiries A meeting convened on 12.9.21 is postponed to 26.9.21 The German company receives approval from the German Ministry of Health to import inflorescences from the farm in Uganda Cancellation of a meeting convened for 25.8.21 Results of Special Meeting held of Aug 19, 2021 Five day extension of the effective date in investment transaction with Dimri Calling of Special Meeting for Sep 12, 2021 Calling of Special Meeting for Sep 12, 2021 1 Voating card Meeting to be held on Sep 12, 2021 Engagement with Yigal Dimri for a ILS 15 million investment in the company against allotment + NIS 10 million loan, conversion of controlling shareholder loan Calling of Special Meeting for Aug 18, 2021 Shelf bid report Subsidiary received the license required to start production operations at the Company’s plant IMC-GMP standard certification received for the company’s plant, and control of the value chain completed Detailed agreement signed for the establishment of a pharmacy chain with Good Pharm Together reports supply of raw materials for Panaxia products which are marketed in France and Germany Association documents – changes in the bylaws Results of General Meeting held of March 17, 2021 Signing of a second addendum to the investment agreement with Hachshara Insurance Phase I, which consisted of certification of the farm in Uganda under the quality standards of the German plant, has been completed Calling of Special Meeting for Mar 17, 2021 Controlling shareholders intend to convert NIS 4.5 million shareholders’ loan to Company shares Subsidiary entered into a medical cannabis production and packaging agreement with a growing farm Import of 1,700 kgs of medical cannabis from Uganda farm to Israel and preparations for its marketing in pharmacies in Israel completed Settlement agreement signed in connection with the Cannabliss acquisition Signing of exclusive distribution agreement and collaborations in and outside of Israel with Sarel, for a total period of 12 years Infrastructure test certificate received for the company’s plant as part of the IMC-GMP process Renewed license received for the company’s growing farm in Israel, valid until December 8, 2023 MOU for marketing of the company’s products in the Good Pharm chain Globus (subsidiary) entered into a NIS 20 million loan and credit agreement with a bank, under which Together will issue unregistered warrants to the corporation IMC-GDP standard certification received for the company’s dispensary, effective until June 2021 Cooperation agreement signed for the distribution in Germany of produce from the company’s farm in Uganda Results of general meeting held on Nov 18, 2020 Obtaining an additional import permit for medical cannabis from the company’s farm in Uganda in the amount of 1700 kg The distribution of cannabis products in the Super-Pharm pharmacy chain has begun Calling of special meeting for Nov 18, 2020 The company’s participation in a pilot in Israel for the export of medical cannabis abroad Obtaining IMC-GSP approval for the company’s factory and trading house Import to Israel of 600 kg of medical cannabis from Uganda farm completed; in preparation for marketing in pharmacies in Israel Update on the completion of medical cannabis harvesting, proceeds pledged to Series A bonds Results of general meeting Binding MOU signed for collaboration on the marketing of medical cannabis products in Brazil A meeting convened on 26.7.20 is postponed to 13.8.20 Another permit received to import medical cannabis from the company’s farm in Uganda, for 600 kg until January 1, 2021 Exclusivity agreement with a pharmacy in Tel Aviv for the sale of medical cannabis products, subject to receipt of approvals A framework agreement for the sale of cannabis flowers for approx. $9.72 million Calling of special meeting For July 26, 2020 Negotiations in progress for a framework agreement for the sale of medical cannabis from the company’s farm in Uganda Clarification – the export to Europe of the company’s products that are manufactured at the Panaxia production facility is subject to the required approvals Page 1 Page 2 Page 3Next →
A voluntary report on the company’s revenues for the third quarter of 2023 in a total sum of approximately NIS 26.5 million
A voluntary report on the company’s revenues for the first quarter of 2023 in a total sum of approximately NIS 21 million
Estimated revenue for the third quarter of 2022 in the amount of approximately NIS 7.5 million and updates related to the company’s activities
Engagement in an agreement for the investment of ILS 10 million in the company, against allotment of some 9.97 million shares and 2.49 million warrants
Understandings for the acquisition of approx. 51% in a pharmacy holding a license to sell medical cannabis
Subsidiary Globus Pharma receives approval from the IMCA to operate a laboratory thereof under the IMC-GMP standard
Another permit received for import of 700 kgs of medical cannabis from the company’s farm in Uganda, effective until March 8, 2022
Initial sale of the company’s products in pharmacies in Germany and negotiations for other significant transactions in the German market
Loan and convertible loan agreement for a total of ILS 25 million with a company controlled by Yigal Dimri (superseding previous agreement)
Winning of tender for the supply of oils to the main pharmacy of the Israel Prison Service, together with another cannabis company
The German company receives approval from the German Ministry of Health to import inflorescences from the farm in Uganda
Engagement with Yigal Dimri for a ILS 15 million investment in the company against allotment + NIS 10 million loan, conversion of controlling shareholder loan
IMC-GMP standard certification received for the company’s plant, and control of the value chain completed
Together reports supply of raw materials for Panaxia products which are marketed in France and Germany
Phase I, which consisted of certification of the farm in Uganda under the quality standards of the German plant, has been completed
Import of 1,700 kgs of medical cannabis from Uganda farm to Israel and preparations for its marketing in pharmacies in Israel completed
Signing of exclusive distribution agreement and collaborations in and outside of Israel with Sarel, for a total period of 12 years
Globus (subsidiary) entered into a NIS 20 million loan and credit agreement with a bank, under which Together will issue unregistered warrants to the corporation
Cooperation agreement signed for the distribution in Germany of produce from the company’s farm in Uganda
Obtaining an additional import permit for medical cannabis from the company’s farm in Uganda in the amount of 1700 kg
Import to Israel of 600 kg of medical cannabis from Uganda farm completed; in preparation for marketing in pharmacies in Israel
Another permit received to import medical cannabis from the company’s farm in Uganda, for 600 kg until January 1, 2021
Exclusivity agreement with a pharmacy in Tel Aviv for the sale of medical cannabis products, subject to receipt of approvals
Negotiations in progress for a framework agreement for the sale of medical cannabis from the company’s farm in Uganda
Clarification – the export to Europe of the company’s products that are manufactured at the Panaxia production facility is subject to the required approvals